Earlier this month, COMPASS Pathways welcomed a White House Executive Order aimed at accelerating treatments for serious mental illness, as it reported two positive phase 3 trials of its COMP360 synthetic psilocybin in treatment-resistant depression and advanced a rolling FDA submission.

Compass Pathways may be the first to benefit from an accelerated approval process.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Shares of several pharmaceutical companies were higher after President Trump signed an executive order aimed at accelerating research, development and access to psychedelic medicines for the treatment of mental illnesses.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled "Clinical Risk,

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based organizations to apply for a grant to create training content for healthcare providers to deliver investigational COMP360 psilocybin treatment,

Compass Pathways PLC CMPS said a White House executive order aimed at accelerating mental health treatment research could help speed access to its experimental psilocybin therapy, which the company says has shown fast and durable results in late-stage clinical trials for treatment-resistant depression.

Compass Pathways remains a pipeline-stage biotech with no current sales, as its lead product, COMP360, is still in clinical trials. Read more about CMPS stock.